Efficacy of Ranibizumab in chronic central serous chorioretinopathy associated with Retinal pigment epithelial detachment: a retrospective study.

BIVAS BALA

Volume : IX, Issue : III, March - 2020

Efficacy of Ranibizumab in chronic central serous chorioretinopathy associated with Retinal pigment epithelial detachment: a retrospective study.

Bivas Bala

Abstract :

AIM: To evaluate the efficacy of intravitreal ranibizumab in chronic central serous chorioretinopathy associated with retinal pigment epithelial detachment. METHODS: In this retrospective study a total of 21 patients diagnosed with chronic central serous chorioretinopathy with pigment epithelial detachment were treated with intravitreal ranibizumab from Jan 2017 to Nov 2019 at Malda medical college, West Bengal, India. From the history sheet we were noted each patient‘s best spectacle corrected visual acuity. Measurement of central macular thickness and subfoveal choroidal thickness were recorded from OCT report. After getting informed consent all patient received intravitreal ranibizumab injection at monthly interval until central macular thickness reduced to normal. Patient were followed up monthly interval for at least 6 months by measuring best corrected visual acuity and central macular thickness as well as subfoveal choroidal thickness. We were taken these data specially of 3 and 6 months for analysis. This data was analyzed statically by pair T test to determine the effectiveness of intravitreal ranibizumab in this condition. RESULTS: all patients showed statically significant improvement within 3 months in terms of best corrected visual acuity, central macular thickness as well as choroidal thickness (p=<0.001) and these were well maintained at 6 months. CONCLUSION: Intravitreal ranibizumab is a good therapeutic option in patients of chronic central retinopathy when it also associated with retinal pigment epithelial detachment.